Due to their competition for binding to the ligands CD80 and CD86 and their antagonistic function in the control of the immune system, one could claim that the ratio of expression levels between CTLA-4 and CD28 in the tumor shifts towards CTLA-4, which would result in a higher CTLA-4/CD28 quotient. The gene discussed is CD86; the disease is neoplasm.